Erschienen in:
01.09.2015 | Day-to-Day Practice
Regorafenib: start low and go slow
verfasst von:
S. Tabchi, M. Ghosn
Erschienen in:
Targeted Oncology
|
Ausgabe 3/2015
Einloggen, um Zugang zu erhalten
Excerpt
Recent advances in the field of molecular biology have ushered in a new era in the treatment of metastatic colorectal cancer (mCRC). Deeper understanding of tumor biology has allowed for the development of multiple agents that inhibit tumorigenesis through variable mechanisms. A backbone chemotherapy regimen can now be combined with bevacizumab or cetuximab/panitumumab for patients with KRAS/NRAS wild-type tumors [
1,
2]. These combinations can be swapped in the second line setting depending on the initial regimen chosen [
3]. …